ARMATA PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 22.90 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-03-25
- ARMATA PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-06-30 was 22.09M shares, a 7.89% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 20.48M shares.
- ARMATA PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 22.90M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2024-12-31 | 22.90M shares 10-K · filed 2026-03-25 | ||
| 2024-06-30 | 22.09M shares 10-Q · filed 2024-08-13 | 22.09M shares 10-Q · filed 2024-08-13 | |
| 2023-06-30 | 20.48M shares 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |